MiMedx Group, Inc $MDXG Shares Purchased by Jump Financial LLC

Key Points

• Jump Financial LLC increased its stake in MiMedx Group by 432.3% in the first quarter, owning 85,162 shares valued at approximately $647,000.
• MiMedx Group reported earnings of $0.10 EPS, surpassing analysts' expectations of $0.06, with revenues totaling $98.61 million for the quarter.
• Research analysts have raised their target price for MiMedx Group from $11.00 to $12.00, reflecting a consensus rating of "Buy" for the stock.

Jump Financial LLC raised its holdings in MiMedx Group, Inc (NASDAQ:MDXG - Free Report) by 432.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 85,162 shares of the company's stock after buying an additional 69,162 shares during the quarter. Jump Financial LLC owned approximately 0.06% of MiMedx Group worth $647,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. AlphaQuest LLC grew its holdings in MiMedx Group by 464.7% in the first quarter. AlphaQuest LLC now owns 51,898 shares of the company's stock valued at $394,000 after purchasing an additional 42,707 shares during the period. Advantage Alpha Capital Partners LP boosted its holdings in shares of MiMedx Group by 53.2% in the 1st quarter. Advantage Alpha Capital Partners LP now owns 81,629 shares of the company's stock valued at $620,000 after purchasing an additional 28,342 shares during the last quarter. Hsbc Holdings PLC grew its stake in shares of MiMedx Group by 32.8% during the 1st quarter. Hsbc Holdings PLC now owns 39,468 shares of the company's stock valued at $295,000 after buying an additional 9,756 shares during the period. Algert Global LLC grew its stake in shares of MiMedx Group by 180.3% during the 1st quarter. Algert Global LLC now owns 74,667 shares of the company's stock valued at $567,000 after buying an additional 48,030 shares during the period. Finally, Meros Investment Management LP increased its holdings in shares of MiMedx Group by 107.7% during the 1st quarter. Meros Investment Management LP now owns 820,605 shares of the company's stock worth $6,237,000 after buying an additional 425,531 shares during the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Stock Down 1.1%

Shares of NASDAQ MDXG opened at $7.10 on Monday. The stock has a fifty day moving average price of $6.78 and a 200 day moving average price of $7.03. The company has a current ratio of 4.39, a quick ratio of 3.90 and a debt-to-equity ratio of 0.08. MiMedx Group, Inc has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a market cap of $1.05 billion, a P/E ratio of 33.81 and a beta of 1.74.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.04. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%.The company had revenue of $98.61 million for the quarter, compared to analysts' expectations of $90.79 million. Research analysts anticipate that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

Analyst Ratings Changes

MDXG has been the topic of a number of research analyst reports. Cantor Fitzgerald lifted their target price on MiMedx Group from $11.00 to $12.00 and gave the company an "overweight" rating in a report on Thursday, July 31st. Wall Street Zen raised MiMedx Group from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $12.00.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group, Inc (NASDAQ:MDXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.